Do People Gain Weight After Stopping Wegovy?

What the trial data actually recorded when people stopped

The STEP 1 extension trial is the most cited evidence here. After 68 weeks on semaglutide 2.4mg, participants in the main STEP 1 study had lost around 15% of their body weight on average, as published in the New England Journal of Medicine. In the follow-up phase, those who switched to placebo regained about two thirds of that weight over the next 52 weeks, ending around 5–6% below their starting weight. Within a year of stopping, most of the metabolic improvements seen during treatment (blood pressure, blood sugar, cholesterol) had also partially reversed.

The reason is straightforward. Semaglutide works by activating GLP-1 receptors involved in appetite regulation and the rate at which the stomach empties. While you take it, hunger signals are quieter and fullness arrives sooner. Once the medicine clears your system, those signals return to roughly where they were before treatment. The body does not "remember" the lower weight as its new normal, weight biology is unfortunately not reprogrammed by a course of medicine the way, say, an infection is cleared by antibiotics.

It is a question our prescribers hear most weeks: "If I stop, will all the weight come back?" The honest answer, grounded in the data, is that significant regain is likely for most people without a plan, but how much and how fast varies considerably depending on what changes were embedded during treatment.

Why the body pulls weight back after stopping Wegovy

Weight is regulated by overlapping biological systems (hormones, metabolic rate, the brain's reward responses to food) and obesity itself alters those systems in ways that persist. Treatment with a GLP-1 medicine does not reverse those underlying changes permanently; it overrides some of them while the medicine is active.

When semaglutide is stopped, appetite typically rebounds to pre-treatment levels within weeks. For many people this feels abrupt: food becomes more appealing again, portion sizes creep up, and the automatic calorie reduction that made Wegovy effective disappears. At the same time, metabolic rate may not have fully recovered from the adaptations the body made during weight loss (a well-documented phenomenon sometimes called metabolic adaptation) making it easier to regain than it was to lose.

This is why the NHS and clinical guidance consistently frame weight management medicines as long-term treatments rather than short courses. The NHS medicines page for semaglutide notes that these medicines are used alongside lifestyle changes, not instead of them, and that the duration of treatment is decided with your clinical team. NICE's recommendation for semaglutide (TA875) includes the condition of use within a specialist weight management programme partly for this reason: the wrap-around support matters as much as the medicine itself.

Does how you stop make a difference?

There is limited trial evidence specifically on tapering versus abrupt stopping, but the clinical reasoning is sound. Stopping abruptly removes the appetite-suppressing effect immediately. A gradual reduction gives more time to consolidate habits, adjust portion sizes consciously, and prepare psychologically for managing hunger without pharmacological support. Many prescribers prefer a managed wind-down, but the right approach depends on why you are stopping and your individual circumstances.

The broader question of what happens in the weeks and months after stopping is covered in more depth on our after stopping Wegovy page, including practical considerations around diet and activity. If you have reached your target weight and are considering stepping down, our guide to stopping Wegovy after weight loss walks through the things worth discussing with a prescriber before you do.

One practical point: the period immediately after stopping is when stopping Wegovy and weight gain is fastest for most people. Having a plan in place before you stop (rather than after you notice the scales moving) makes a meaningful difference.

Can anything limit how much weight returns?

The honest answer is: yes, to a degree, but not completely for most people without continued support. People who have genuinely changed eating patterns and built regular physical activity into their routines during treatment do tend to regain less, and more slowly, than those who relied primarily on the medicine's appetite suppression without addressing habits. That distinction matters for how treatment is approached from day one.

Some people consider switching to a different medicine or dose rather than stopping outright, our weight management with Wegovy page explores long-term treatment as a strategy. Others look at whether tirzepatide (Mounjaro) might be more appropriate, given its stronger average results in head-to-head trial evidence. What suits you is a clinical decision, not a marketing one, and it involves your full health picture.

If you are thinking about starting treatment and want to understand what a realistic long-term plan looks like, including the cost of Wegovy in the UK over time, that context is worth having before you begin. The free consultation at nume is the place to talk through your options with a GPhC-registered prescriber who can assess what is right for you specifically. There is no obligation, and no algorithm involved.